Epoetin Alfa
**Epoetin alfa** is a biosynthetic form of the glycoprotein human hormone erythropoietin (rHuEPO). It is primarily used in veterinary medicine to treat non-regenerative anemia associated with **chronic renal failure (CRF)** in dogs and cats. Because it is a human recombinant protein, its use in companion animals carries a significant risk (20-70% incidence) of inducing **anti-erythropoietin autoantibodies**. These antibodies can cross-react with the animal's own endogenous erythropoietin, leading to profound, transfusion-dependent refractory anemia. Consequently, many clinicians reserve epoetin alfa as a "last ditch effort" when the packed cell volume (PCV) drops into the teens. > **Clinical Pearl:** Patients receiving epoetin alfa almost universally require concurrent **iron supplementation** to support the sudden increase in red blood cell production.
Mechanism: Erythropoietin is an endogenous hormone primarily produced by the kidneys that regulates erythropoiesis. * **Receptor Binding:** Epoetin alfa binds to **erythropoietin receptors** on the surface of committed erythroid progenitor cells in the bone marrow. * **Proliferation & Differentiation:** This binding activates intracellular signaling pathways (such as JAK2/STAT5) โ stimulates the survival, proliferation, and differentiation of red cell precursors. * **Reticulocyte Release:** It also accelerates the release of reticulocytes from the bone marrow into the systemic circulation, ultimately increasing the hematocrit and hemoglobin levels.
Dosing by species
- Adjunctive therapy for anemia associated with endstage renal disease ยท Initially, 100 Units/kg SC 3 times weekly (or 48.4-145 Units/kg SC 3 times a week). ยท SC ยท 3 times weekly ยท Ongoing ยท Target hematocrit is 30-40%.
- Anemia associated with endstage renal disease (PCV <20%) ยท 75-100 Units/kg SC three times a week until PCV is in the low normal range (35%), then reduce dose and frequency to 50-75 Units/kg two times per week. ยท SC ยท 3 times a week initially ยท Ongoing ยท Administer iron at start of regime and until appetite is good.
- Problematic clinical signs and PCV <20% ยท Initially, 100 Units/kg SC 3 times per week. ยท SC ยท 3 times per week ยท Ongoing ยท Provide oral supplementation with ferrous sulfate (5-50 mg per cat per day). Reduce to twice per week when target PCV (30-40%) is reached.
- Anemia ยท 50-150 Units/kg IM 3 times weekly; may decrease to once weekly if RBC indices are significantly improved ยท IM ยท 3 times weekly ยท Ongoing
- Anemia (Rabbits) ยท 50-150 Units/kg SC every 2-3 days until PVC is normal; then once weekly (q7 days) for at least 4 weeks ยท SC ยท every 2-3 days initially ยท at least 4 weeks maintenance
- Adjunctive therapy for anemia associated with endstage renal disease ยท Initially, 100 Units/kg SC 3 times weekly, until the bottom of the target hematocrit range of 37-45% is attained. Once attained, change to twice weekly. As hematocrit approaches upper target, reduce to once weekly. Maintenance generally 75-100 Units/kg SC 1-2 times weekly. ยท SC ยท 3 times weekly initially ยท Ongoing ยท A lower initial dosage of 50-100 Units/kg 3 times weekly may be used. Iron supplementation required.
Routes of administration
Contraindications
- Uncontrolled hypertension
- Hypersensitivity to epoetin alfa
- Formation of significant autoantibodies with prior treatment
- Equines (not recommended for use)
Adverse effects
- Autoantibody formation (leading to refractory anemia)
- Systemic hypertension
- Vomiting
- Seizures
- Uveitis
- Iron depletion
- Local reactions at injection sites
- Fever
- Arthralgia
- Mucocutaneous ulcers
- Polycythemia (with chronic overdosage)
Drug interactions
- Androgens ยท May increase the sensitivity of erythroid progenitors; safety of this combination is not fully determined.
- Desmopressin ยท Concurrent use with EPO can decrease bleeding times.
- Probenecid ยท Has been demonstrated to reduce the renal tubular excretion of EPO; clinical significance remains unclear.
- Iron supplements ยท Synergistic/Required; EPO increases demand for iron to synthesize hemoglobin for new RBCs ยท minor
Monitoring
- Hematocrit / PCV (weekly to every other week initially, then every 1-2 months)
- Blood Pressure (at least monthly initially)
- Renal Function Status
- Iron status (serum iron, TIBC)
- RBC indices
Overdose
Acute overdoses appear to be relatively free of adverse effects. Single doses of up to 1600 Units/kg in humans demonstrated no signs of toxicity. **Chronic overdoses** may lead to polycythemia or other adverse effects. Cautious phlebotomy may be employed should polycythemia occur.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโs current label.